MCRB Seres Therapeutics, Inc.

9.57
-0.32  -3%
Previous Close 9.89
Open 9.96
Price To book 3.58
Market Cap 386.53M
Shares 40,390,000
Volume 98,158
Short Ratio 22.53
Av. Daily Volume 243,106

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b initiated July 2016. Data due 2H 2017
SER-262
Primary Clostridium Difficile infection (CDI)
Phase 2 interim data did not meet primary endpoint. Noted May 4, 2017 that an additional Phase 2 trial to be initiated mid-2017.
SER-109
Recurrent C. Difficile infection
Phase 1b initiated December 2015. Enrollment ongoing as of May 2016. Data due 2H 2017.
SER-287
Mild-to-Moderate Ulcerative Colitis

Latest News

  1. Edited Transcript of MCRB earnings conference call or presentation 4-May-17 12:00pm GMT
  2. Seres Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MCRB-US : May 5, 2017
  3. Seres Therapeutics reports 1Q loss
  4. Seres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress
  5. Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
  6. Seres Therapeutics to Host First Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2017
  7. Seres Therapeutics, Inc. – Value Analysis (NASDAQ:MCRB) : April 19, 2017
  8. Seres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : April 18, 2017
  9. Seres Therapeutics Inc (MCRB) Announces New “Poop Pill” Phase 2 Study
  10. Edited Transcript of MCRB earnings conference call or presentation 16-Mar-17 12:00pm GMT
  11. Why GoPro, Barnes & Noble, and Seres Therapeutics Jumped Today
  12. Here's What's Lifting Seres Therapeutics Inc.'s Stock Price Today
  13. Biotech Premarket Movers: Seres, PTC, Inovio
  14. Seres gets FDA mulligan on microbiome drug, eyes pivotal trial
  15. Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update
  16. Seres Therapeutics to Initiate New SER-109 Clinical Study
  17. Seres Therapeutics to Host Fourth Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on March 16, 2017
  18. Seres Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
  19. Why Seres Therapeutics (MCRB) Might Surprise This Earnings Season